Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 45Uterine Cervical Neoplasms 22Fallopian Tube Neoplasms 20Carcinoma, Ovarian Epithelial 15Neoplasms 8Endometrial Neoplasms 8Lung Neoplasms 7Breast Neoplasms 5Stomach Neoplasms 4Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Gestational Trophoblastic Disease 4Vulvar Neoplasms 3Peritoneal Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Colorectal Neoplasms 3Uterine Neoplasms 2Sarcoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Laryngeal Neoplasms 2Hydatidiform Mole 2Gynecologic Cancer 2Glioblastoma 2Colonic Neoplasms 2Cholangiocarcinoma 2

Interventions

anlotinib 2Ocoxin 2Bevacizumab 2pembrolizumab 1olaparib 1niraparib 1lenvatinib 1catumaxomab 1Papanicolaou Test 1Paclitaxel 1Human Papillomavirus DNA Tests 1Filgrastim 1Drug Therapy 1Colposcopy 1Cell Count 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Drug Therapy × Gynecologic × Clear all
NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡